Introduction
============

Genome wide association studies (GWAS) have identified a large number of single nucleotide polymorphisms (SNPs) in a segment of about 2 Mb mapping to human chromosome 8q24 (chr.8q24) that are linked to susceptibility for different diseases including cancers of the prostate, breast, esophagus, head and neck, ovarian, colon, and pancreas (Easton and Eeles, [@B21]; Grisanzio and Freedman, [@B31]; Figure [1](#F1){ref-type="fig"}). One gene found within this chr.8q24 region, *MYC*, stands out as the most likely candidate to be functionally linked to these cancer risk-associated SNPs given its well defined role as an oncogenic transcription factor (Meyer et al., [@B56]). In addition, to GWAS linkage, there are several other cancer-associated features of this region of chr.8q24 (128.0--130.0 Mb) that serve to further establish the significance of 8q24 in driving tumor development that also complicates its' study as well. While MYC is recognized to be the most frequently amplified protein-coding gene across all cancer types (Beroukhim et al., [@B9]), the fact that increased copies of *MYC* are often accompanied by co-amplification of an adjacent non-coding locus, *PVT1* is not fully appreciated nor understood (Asker et al., [@B5]; Shtivelman and Bishop, [@B68]; Bakkus et al., [@B6]; Minarovits et al., [@B59]; Figure [1](#F1){ref-type="fig"}). Furthermore, chromosomal translocations that appear to target *MYC* are often found in Burkitt's lymphoma (BL) and other non-Hodgkin's lymphoma types, but a subset of these lymphomas (15--20%) exhibiting breakpoints as far as 300--400 kb downstream of *MYC* on 8q24, is a feature that complicates the hypothesis that singular *MYC* is always the intended target.

![**The 8q24 gene desert**. Shown along the 1.8-Mb region of human chromosome 8q24 (128.0 Mb thru 129.8 Mb) are the extent of the protein encoding *MYC* transcript (blue), the lincRNA *PVT1* (dark blue), the putative lincRNA *PRNCR1* (dark blue), the less defined *POU5F1P1* transcript (light blue), and the microRNAs, *miR-1204* through *miR-1208*. Also depicted are the locations of GWAS defined SNPs (1--28) associated with disease susceptibility (see Table [1](#T1){ref-type="table"} for details). The bars denote focused regions of amplification (shown in red), chromosomal translocation (blue), viral integration (yellow), or deletion (green) that have been observed in different tumor types (see text for details).](fgene-03-00069-g001){#F1}

In addition to *MYC*, the transcripts, *POU5F1B* and *PVT1*, reside within the 128.0- to 130.0-Mb region of chr.8q24 most often associated with GWAS, translocation, or integration events (Figure [1](#F1){ref-type="fig"}). The *POU5F1B* gene was long considered as a pseudogene (*POU5F1P1*), however, a recent report now proposes that it could encode a weak transcriptional activator (Kastler et al., [@B44]). The *PVT1* locus expresses several alternatively spliced non-coding transcripts (Shtivelman et al., [@B70]; Huppi et al., [@B40]; Shtivelman and Bishop, [@B69]) and *PVT1* is the host to a cluster of microRNAs (miR-1204 ∼ 1208; Huppi et al., [@B41]). Nevertheless, no clear functional role for any of these transcripts has been identified and the paucity of coding region genes within this chromosomal region has lead to its description as the "8q24 gene desert" (Ghoussaini et al., [@B28]; Wasserman et al., [@B80]). In this review we discuss the growing evidence that the 8q24 gene desert in fact, has a complex pattern of transcription that, in addition to *MYC*, should be considered when assaying for disease candidate loci.

SNPs Across the 8q24 Region are Associated with Disease-Risk
============================================================

Several years ago, our laboratory and others (Rothberg and Otto, [@B66]; Siwarski et al., [@B71]) identified SNPs within the coding region of *MYC* (S11N, CAA-33, and S288K). For one of the SNPs (S288K), we were able to follow the inheritance of the rare non-synonymous variant allele in a small family pedigree and compare expression of *MYC* between the two alleles. Our report highlighted the possibility of reduced expression from two rare variant *MYC* alleles (S288K and CAA-33) and thus, demonstrated for the first time, differential expression levels of germline MYC alleles (Siwarski et al., [@B71]). At the time, we could not distinguish whether reduced MYC expression was due to the differential binding of transcription factors (such as YY1) to the actual SNP sequence or whether associated 5′ or 3′ base changes accompanied the presence of these alleles. The limitations of this study were the small size of the cohort, coupled with the inability to find the rare variant outside of this family. However, with development of high throughput, population-based SNP analysis, GWAS are empowered with the ability to avoid false positive discovery through study of large, well-documented case control and cohort groups that avoid bias as a result of for example, survivorship and sample integrity.

One of the first cancer susceptibility GWAS to be published linked prostate cancer susceptibility to SNP variants in the region of chr.8q24, far upstream of *MYC* in the Icelandic population (Amundadottir et al., [@B3]). Subsequent reports from the study of Caucasian men in Sweden and the US further confirmed the linkage to prostate adenocarcinoma and narrowed the region of risk to two alleles, the −8 allele at the marker DG8S737 and the A allele of rs1447295 (Amundadottir et al., [@B3]). The incidence of the DG8S737 marker was also increased in patients at risk for prostate cancer in an independent study of African Americans but this study also suggested that differences in the overall frequency of the DG8S737 allele in Caucasians versus African Americans might bias the link to prostate cancer (Freedman et al., [@B27]). As a result of the many additional studies of SNPs from the region of chr.8q24 (Gudmundsson et al., [@B33]; Haiman et al., [@B35]; Yeager et al., [@B85]; Eeles et al., [@B22]; Ghoussaini et al., [@B28]; Thomas et al., [@B74]), several sub-regions of susceptibility can be assigned to prostate cancer risk in a region of ∼2.7 Mb of DNA extending from a position centromeric to *POU5F1B* to include a region of several hundred kb of DNA proximal of *MYC* (Figure [1](#F1){ref-type="fig"}; Table [1](#T1){ref-type="table"}).

###### 

**SNPs associated with risk in 8q24**.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  SNP          Disease                                     Position    *P*-value        Reference
  ------------ ------------------------------------------- ----------- ---------------- -----------------------------------------------------------------------------------------------------------------------------------------------------
  rs1016343    Prostate cancer                             128093297   1 × 10^−7^       Eeles et al. ([@B22])

  rs16901979   Prostate cancer                             128124916   3 × 10^−14^      Gudmundsson et al. ([@B33])

  rs2456449    Chronic lymphocytic leukemia                128192981   8 × 10^−10^      Crowther-Swanepoel et al. ([@B19])

  rs16902094   Prostate cancer                             128320346   6 × 10^−15^      Gudmundsson et al. ([@B33])

  rs378854     Prostate cancer                             128323819                    Meyer et al. ([@B55])

  rs13281615   Breast cancer                               128355618   5 × 10^−12^      Easton and Eeles ([@B21])

  rs1562430    Breast cancer, prostate cancer              128387852   6 × 10^−7^       Turnbull et al. ([@B77])

  rs10505477   Ovarian cancer                              128407443   2 × 10^−3^       Ghoussaini et al. ([@B28]), Zanke et al. ([@B87])

               Colon cancer                                            3 × 10^−11^      

  rs10808556   Ovarian cancer                              128413147                    Ghoussaini et al. ([@B28])

  rs6983267    Ovarian cancer\                             128413305   9.9 × 10^−3^\    Yeager et al. ([@B85]), Ghoussaini et al. ([@B28]), Eeles et al. ([@B22]), Thomas et al. ([@B74]), Tomlinson et al. ([@B75]), Berndt et al. ([@B8])
               Colon cancer\                                           1 × 10^−14^\     
               Prostate cancer                                         9 × 10^−13^      

  rs7837328    Colon cancer                                128423127                    Berndt et al. ([@B8])

  rs7000448    Prostate cancer                             128441170                    Ghoussaini et al. ([@B28])

  rs1447295    Prostate cancer, esophageal cancer          128485038   2 × 10^−19^      Gudmundsson et al. ([@B33]), Yeager et al. ([@B85]), Lochhead et al. ([@B51])

  rs4242382    Prostate cancer                             128517573   3 × 10^−19^      Thomas et al. ([@B74])

  rs7017300    Prostate cancer                             128525268                    Yeager et al. ([@B85])

  rs10090154   Prostate cancer                             128532137                    Cheng et al. ([@B17])

  rs7837688    Prostate cancer                             128539360                    Yeager et al. ([@B85]), Berndt et al. ([@B8])

  D8S1128      Type II diabetes                            128595148   2 × 10^−3^       An et al. ([@B4])

  rs9642880    Bladder cancer                              128718068   7 × 10^−12^      Ghoussaini et al. ([@B28]), Kiemeney et al. ([@B45])

  rs11993333   End stage renal disease (type I diabetes)   128992487   1.3 × 10^−3^     Hanson et al. ([@B36])

  rs2720709    End stage renal disease (type I diabetes)   129058356   2 × 10^−5^       Hanson et al. ([@B36])

  rs2648862    End stage renal disease (type I diabetes)   129061785                    Hanson et al. ([@B36])

  rs2608053    Hodgkin's lymphoma                          129075832   1.16 × 10^−7^    Enciso-Mora et al. ([@B23])

  rs1499368    End stage renal disease (type I diabetes)   129094589   6.1 × 10^−3^     Hanson et al. ([@B36])

  rs2019960    Hodgkin's lymphoma                          129192271   1.26 × 10^−13^   Enciso-Mora et al. ([@B23])

  rs1516982    Ovarian cancer                              129533646                    Goode et al. ([@B30])

  rs10088218   Ovarian cancer                              129543949   8 × 10^−15^      Goode et al. ([@B30])

  rs10098821   Ovarian cancer                              129559228                    Goode et al. ([@B30])
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

While many of the chr.8q24 associated SNPs were originally identified as susceptibility markers for prostate cancer, additional SNPs in the region of chr.8q24 have now been associated with many other cancers (Figure [1](#F1){ref-type="fig"}; Table [1](#T1){ref-type="table"}). For example, two SNPs (i.e., rs13281615 and rs1562430) are linked to breast cancer (Easton and Eeles, [@B21]), and the SNP rs9642880 has been uniquely associated with bladder cancer (Ghoussaini et al., [@B28]). Some SNPs including rs10505477 (positioned at 128.40 Mb), rs1562430 (position 128.38 Mb), and rs6983267 (position 128.41 Mb) are found to be associated with increased susceptibility in multiple cancers whereas some SNP variants appear to be unique susceptibility markers to a singular cancer type. An example of the unique cancer based SNP is rs2456449, which to date, has only been associated with susceptibility to B-cell chronic lymphocytic leukemia (Crowther-Swanepoel et al., [@B19]). In addition to the SNP variants located to the proximal (5′) side of *MYC*, a few susceptibility variants have been identified 3′ of *MYC* in the PVT1 region.

A number of SNP variants for ovarian cancer have been identified on both the 5′ (Ghoussaini et al., [@B28]) and 3′ side of *MYC* (Goode et al., [@B30]), respectively. Although this might implicate *MYC* as the central target in ovarian cancer, some doubt as to the strength of these GWAS studies has been raised, as the positioning of the risk alleles appears to be report specific (White et al., [@B83]; Braem et al., [@B11]). The fact that ovarian cancer is a heterogeneous disease may also be a factor leading to the lack of reproducibility in assigning ovarian cancer risk. Nevertheless, independent findings such as, frequent amplification in ovarian cancer (see below) still suggests that the 8q24 locus may be an important region in the progression of ovarian cancer.

The presence of multiple loci associated with susceptibility to different cancer specificities raises another provocative question as to whether the clustering of many 8q24 SNP variants could be pleiotropic. For instance, is the region of 8q24 unique in the genome in harboring many cancer risk loci or will additional regions of multiple cancer risk eventually be identified. A possible clue comes from a study of disease susceptibility in end stage renal disease (ESRD). A series of SNP variants located within the *PVT1* region have been identified as candidate loci for ESRD in type 1-diabetes (Hanson et al., [@B36]). Further characterization of the *PVT1* gene in diabetic kidney disease studies suggest a possible molecular mechanism for the non-coding *PVT1* gene in extracellular matrix (ECM) accumulation (Alvarez and DiStefano, [@B2]). More importantly, it relies on a function of *PVT1* independent of *MYC*, in the progression of ESRD and it underscores the possibility that the 8q24 locus is multifaceted and not simply dominated by a single regulatory element or gene. Interestingly, diabetes and cancer are known to share common risk factors although for prostate cancer in particular, the risk is inversely correlated with diabetes (Giovannucci et al., [@B29]).

The challenge of population-based cancer susceptibility in GWAS is the establishment of a connection between the position of SNP variants and functionality. This is critical because most cancer-associated SNP variants have been found to be synonymous, mapping to regions of intervening DNA, often very distant from candidate protein-coding genes. This has been especially apparent in the chr.8q24 region where *MYC* resides as the most likely candidate gene target yet establishing a functional correlation with MYC expression has been surprisingly inconsistent.

MYC
===

The *MYC* gene (128748315--128753680) is comprised of three exons; exon 1 is non-coding, exons 2 and 3 are protein-coding (for review see Pelengaris and Khan, [@B60]). The translation start signal (TSS) in exon 2 generates a protein of 439 amino acids (64 kDa). Alternative translational initiation start sites are capable of generating a larger protein, p67 and a shorter one, MYC. Transcription of the *MYC* gene initiates from one of two promoters, P1 or P, and there are several well-characterized elements that bind the *MYC* promoter including CT, FUSE, TFIIH, and FIR. When chromosomal translocations displace P1 and P2 with the immunoglobulin enhancers (as observed in BL), de-regulated *MYC* expression persists from a series of cryptic promoters within the intron.

*MYC* is one of the most studied oncogenes stemming from its association with a large number of diseases and indeed, a link to *MYC* expression for alleles associated with particular SNPs would be a first candidate gene of choice. In concert with this hypothesis, Sole et al. ([@B72]) found consistent up-regulated expression of *MYC* in normal prostate samples with regard to at least one risk locus (rs1447295). However, another group (Pomerantz et al., [@B63]) failed to find any correlation between *MYC* expression and a risk allele (including rs1447295) in their normal prostate samples. Possible reasons for the inconsistencies could be differences in tissue purity or integrity of RNA, but a third study now suggests that the ideal window to examine the affects of risk allele and expression of *MYC* may be earlier in the formation of the tumor than what is usually tested (Wasserman et al., [@B80]). *MYC* expression in association with disease-risk alleles has also been examined in colorectal tissues and once again, three independent studies have failed to establish any correlation between *MYC* expression and the risk alleles (Zanke et al., [@B87]; Pomerantz et al., [@B64]; Tuupanen et al., [@B78]). In a more detailed study of a single risk allele rs6983267 in colorectal samples, Wright et al. ([@B84]) dissected *MYC* expression into specific chromosomes and found *MYC* expression to be allele specific. As noted above, SNPs both upstream and downstream of *MYC* have been linked to ovarian cancer suggesting *MYC* is the target gene in this case. However, studies of risk-associated alleles in ovarian cancer have failed to show correlation with *MYC* expression (Goode et al., [@B30]). Thus, the issue of association between risk alleles and *MYC* expression remains inconsistent.

The co-localization of epigenetic landmarks with SNP variants could also be a source of transacting regulation of nearby genes such as *MYC*. In fact, chromatin immunoprecipitation studies have found acetylation and histone markers consistent with regulatory activity for one SNP variant (rs6983267) in colorectal cancer and reporter assays have shown allele specific enhancement of *MYC* expression in colorectal cancer lines (Pomerantz et al., [@B64]; Wright et al., [@B84]). Several other SNP variants in prostate and breast cancer show similar properties in a tissue specific fashion (Ahmadiyeh et al., [@B1]). Further, the rs6983267 risk allele has been shown to bind avidly to the TCF7L2 transcription factor compared to the non-risk allele (Sotelo et al., [@B73]). The question is, do these enhancers interact with *MYC* or with other genes in the chr.8q24 region or with transacting elements elsewhere in the genome? Several studies have now demonstrated direct binding of the rs6983267 risk region with promoter regions of *MYC* in colorectal cancer cell lines (Pomerantz et al., [@B64]; Wright et al., [@B84]) and prostate cancer cell lines (Sotelo et al., [@B73]). However, the results in the prostate study are conflicting in that the greatest enhancer activity was found not in association with the risk locus rs3983267 but with a neighboring region of DNA (Sotelo et al., [@B73]). Furthermore, enhancer activity associated with rs3983267 was seen only in the presence of both TCF7L2 and CTNNB1 and reporter assays showed enhanced expression with the non-risk allele compared to the risk allele. Nevertheless, Wasserman et al. ([@B80]) are able to show that the risk allele does indeed bind more avidly than the non-risk allele *in vivo* (prostate and coagulating glands). With the inconsistency of these results, it is apparent that the lack of correlation between *MYC* expression and the presence of the risk allele in prostate cancer would indicate that either the window of accessibility is earlier in the development of the tumor or the gene target is not *MYC*. Consistent with this argument are the studies of Cole and colleagues (Wright et al., [@B84]) who show that the rs3983267 enhancer has significant binding activity to both *MYC* and also the neighboring *PVT1* promoters. While this could be explained as co-regulated expression of both MYC and PVT1, it is also possible that the intended target in some of these malignancies is something other than *MYC*. For example, in an examination of expression in prostate cancer specimens, significant increased expression was observed with at least one PVT1 transcript variant (Pomerantz et al., [@B64]).

PVT1
====

The "plasmacytoma variant translocation" or *PVT1* locus was originally defined as a cluster of chromosomal translocation or viral integration breakpoints located several hundred kilobases (kb) downstream of *MYC* in B-cell or T cell lymphomas (Erikson et al., [@B24]; Webb et al., [@B81]). The term "variant" referred to the frequency of chromosomal breakpoints in BL or mouse plasmacytoma found in the *PVT1* region (10--20%) compared to those breakpoints found near *MYC* (80--90%). Although the breakpoints fuse a segment of *PVT1* with immunoglobulin light chain gene, it was originally thought that interruption of *PVT1* simply lead to de-regulated expression of nearby *MYC*. However, lack of consistent up-regulation of *MYC* in a number of lymphomas, lead to the search and discovery of *PVT1* transcripts in both human and mouse (Shtivelman et al., [@B70]; Huppi et al., [@B40]). The human *PVT1* transcript starts with either exon 1a (128806779) or exon 1b (128808208) ∼40--42 kb 3′ of the *MYC* transcript and with extensive alternative splicing, the *PVT1* transcript can extend 1.1 Mb distal to *MYC* to create transcripts of between 2.7 and 3.3 kb in length (Figure [2](#F2){ref-type="fig"}). Among the human *PVT1* transcripts identified, expression of exon 1a far out-weighs the utilization of exon 1b. Most importantly, exons 1a and 1b are mutually exclusive in that they have not been found spliced together in cDNAs. In fact, it is possible that exon 1b is only expressed in malignant cell lines containing amplified *PVT1* (Guan et al., [@B32]). Although the most commonly used exons are 1a, 2, 3b, 4b, 7, 8, and 9, it should be emphasized that alternative splicing in different tissues makes it difficult to assign a single reference consensus sequence (Figure [2](#F2){ref-type="fig"}). One of the most remarkable features of the *PVT1* locus since the discovery of cDNA clones in the early 1990s is the conservation of transcriptional activity in this region across synteny. *PVT1* transcripts have been cloned from rat (Koehne et al., [@B48]; Tsichlis et al., [@B76]), mouse (Huppi et al., [@B40]), and human (Shtivelman et al., [@B70]) and yet no consistent protein encoding open reading frames could be established despite the utilization of as many as 8--10 alternative exons. Despite the consistent localization of *PVT1* transcripts close to *MYC* in several different species, the inconsistency of the location of exons in these species coupled with a complete lack of sequence conservation across species suggested early on to investigators, including ourselves, that *PVT1* was not translated as a protein product from the normal transcript. Thus *PVT1* became an early example of a non-coding RNA (for a current review of non-coding RNA see Esteller, [@B25]), similar to the loci H19 (Brannan et al., [@B12]) and XIST (Brockdorff et al., [@B13]; Brown et al., [@B14]). Even though suggestions were made that *PVT1* could act as a regulatory RNA, a lack of defined function left *PVT1* transcription as a curiosity (Huppi and Siwarski, [@B39]).

![**Transcripts from the 8q24 region downstream of MYC**. *MYC* (blue) is used as the anchoring position for depicting the series of alternative spliced transcripts from *PVT1* and the location of miRNAs (*miR-1204* through *miR-1208*). The positions of the exons are located with respect to the chromosome 8 address (128.80--129.20 Mb) and are colored with respect to whether they are frequently used (dark blue), infrequently used (yellow), or part of a putative lincRNA (orange). Shown are the *PVT1* exon composition observed in cDNA clones from the tissues indicated \[Leu1, Leu2, 4, Leu5 (Huppi, unpublished), A8, B6, B4, B9 (Guan et al., [@B32]) Y2, NR_003367 (Shtivelman et al., [@B70]), AC103705.1-201 (Ensembl annotation lincRNA pipeline)\]. Only unique variants have been listed to abbreviate the list. The reader is encouraged to review the complete list online (UCSC database).](fgene-03-00069-g002){#F2}

Our improved understanding of the importance of long RNAs (lincRNAs) and the finding of multiple disease-risk SNPs close to the *PVT1* have prompted renewed interest and investigation into this locus. It was a search for methylated chromatin (H3K4me3 and H3K36me3) that led to the prediction, and ultimately, the identification of three mouse *PVT1* cDNAs (Pvt1-201, Pvt1-202, Pvt1-203) as potential lincRNAs (Guttman et al., [@B34]). As a human lincRNA counterpart in the PVT1 region has been predicted from the Ensembl lincRNA annotation pipeline (AC103705.1-201 in Figure [2](#F2){ref-type="fig"}) there is a potential for lincRNA based *PVT1* function, but this still needs to be validated *in vivo*. Recent evidence has also noted *PVT1* as among the top fold decrease in expression during the transition from induced pluripotent stem cells (iPSCs) to neurons (Lin et al., [@B50]). Additional evidence for a functional role for *PVT1* has also come from the study of the effect of silencing of *PVT1* transcripts via RNAi. Specifically, Gray and colleagues were able to induce apoptosis in ovarian or breast cell lines following silencing of *PVT1* in cell lines with amplified chr.8q24 but they found no apoptosis in non-amplified cell lines (Guan et al., [@B32]). Why 8q24 amplified cell lines as opposed to non-amplified cell lines are uniquely susceptible to silencing of *PVT1* is puzzling and will need further clarification. Evidence that *PVT1* was acting independently of *MYC* in these experiments came from the fact that inhibition of *MYC* alone failed to induce apoptosis. Further, a recent publication (Meyer et al., [@B55]) has identified a risk variant rs378854 that is located within a DNase hypersensitive site and within a repetitive region ∼0.5 Mb upstream of the *PVT1* promoter (also upstream of *MYC*). This region had not been detected previously due to the need to extract repetitive sequences from DNase analysis. This risk allele (rs378854) appears to be prostate tissue specific. Binding of the transcription factor YY1 is observed on the risk variant and further studies with chromatin conformation capture (3C) have shown the ability of this region to interact long range with *MYC*, *PVT1* (but not *FAM84B* a gene located centromeric of *POU5F1B*). This study also correlated reduced expression of *PVT1* (in the absence of a change in *MYC* expression) with the loss of YY1 binding to the risk allele. Another hint at a possible functional role for *PVT1* has been found in a transposon-based genetic screen of Gemcitabine sensitivity in pancreatic cells (You et al., [@B86]). Although this study needs to be validated, transposon-based inactivation of the *PVT1* transcript alone (independent of *MYC*) resulted in increased sensitivity to Gemcitabine in the pancreatic cell line ASPC-1 whereas over-expression of *PVT1* led to increased cellular proliferation even in the presence of Gemcitabine.

The discovery of miRNAs several years ago also encouraged us to re-examine the *PVT1* locus for the presence of RNAs that may have been too small to be detected in the original cDNA cloning studies. Our detailed study of the refined region of 400 kb surrounding the PVT1 region lead to the discovery of a cluster of miRNAs (miR-1204 ∼ 1208) residing within the *PVT1* locus but not overlapping with any *PVT1* exons (Huppi et al., [@B41]). One miRNA, *miR-1204* resides adjacent to the little used exon 1b of *PVT1* and includes a very short overlapping segment with the exon. From 5′ RACE experiments, it is clear that *miR-1204* and *PVT1* share promoters and probably share regulatory elements for the most part as expression of both *PVT1* and *miR-1204* often appear to respond together (Barsotti et al., [@B7]). Each of the other miRNAs, *miR-1205* ∼ *1208*, appear to be differentially regulated from *PVT1* and *miR-1204* (Huppi et al., [@B41]). Interestingly, in the study of prostate cancer specimens and the risk allele rs378854, Ponder and colleagues observe evidence of a possible correlation between expression of *miR-1208* and prostate cancer (Meyer et al., [@B55]), although this finding will need further study. In another recent study of human diploid fibroblasts, *miR-1204* was noted as having the greatest increase in expression levels among miRNAs in senescent versus early passage fibroblasts (Marasa et al., [@B54]) and *miR-1204* was also noted as showing increased expression during the iPSCs neuronal differentiation (Lin et al., [@B50]). Although preliminary, these findings implicate miR-1204 in the subset of miRNAs associated with suppression of tumor growth. Our recent findings have shown that *PVT1* and *miR-1204* are both responsive to Daunorubicin treatment in a number of cell lines including colon, fibroblast, and lymphoid (Barsotti et al., [@B7]). As the presence of a p53 binding site in the promoter region of *PVT1* and *miR-1204* is the basis for the Daunorubicin mediated response to DNA damage in several different tissue types, these results implicate a pro-survival role for *PVT1* consistent with the findings of You et al. ([@B86]) in the Gemcitabine experiments in pancreatic cells. In contrast, activation of *miR-1204* by binding of p53 appears to be anti-proliferative suggesting a very interesting series of opposing actions of *PVT1* versus *miR-1204*. Further studies on the apparent opposing actions of *PVT1* and *miR-1204* are being carried out.

Studies in type 1-diabetes ESRD (Millis et al., [@B58]; Alvarez and DiStefano, [@B2]) have ruled *MYC* out as the candidate gene whereas certain variants of the *PVT1* transcript were highly expressed in renal cells and specifically up-regulated in hyperglycemic conditions. Furthermore, silencing of *PVT1* appeared to reduce the expression of specific genes, including *FN1*, *COL4*, *TGFB1*, and *PAI-1* that are involved in the composition of the ECM affecting glomerular filtration (Alvarez and DiStefano, [@B2]). Perhaps for the first time, a specific function might be assigned to the non-coding *PVT1* transcript independent of *MYC*, but this finding will need to be confirmed.

*POU5F1B* and *PRNC1*
=====================

A series of transcripts that map centromeric to the GWAS SNP variants, 1.2 Mb proximal to *MYC* and just distal to FAM84B on chr.8q24 are associated with *POU5F1B* (128427857--128429455). *POU5F1B* was originally considered to be a pseudogene (POU5F1P1) of *OCT4*, an important transcription factor involved in stem cell pluripotency and reprogramming. Extensive 5′ RACE experiments have identified several alternatively spliced transcripts (Kastler et al., [@B44]), differing in their TSS that all seem to splice to a single main exon carrying the ORF. The transcript variant with the most distant TSS actually starts within the intron of *FAM84B* generating a transcript that extends over a region of 860 kb. There is evidence that transcription of *POU5F1B* is increased in many cases of prostate cancer, whereas some common prostate cell lines (i.e., DU-145, PC-3) do not appear to express the transcript. Kastler et al. ([@B44]) have used an antibody to Oct4 assuming that Oct4 is not expressed in prostate tissue to demonstrate that a protein is indeed detectable in prostatic tissue. However, the signal for this protein is weak and direct demonstration of a protein specific to POU5F1B needs to be performed to validate these results. In addition, a long non-coding RNA (*PRNCR1*) of 13 kb was recently isolated from one of the recognized susceptibility regions just distal to the SNP variant rs1456315 (Chung et al., [@B18]). Up-regulated expression of *PRNCR1* has been noted in a number of microdissected prostate cancer samples and prostate intraepithelial neoplasia compared to normal adjacent tissue (Chung et al., [@B18]). Further validation of this transcript will be needed to determine whether it plays a role in prostate cancer or other cancers.

Cancer-Associated Genomic Alterations and the 8q24 Region
=========================================================

In addition to the clustering of cancer-associated SNPs that map to chr.8q24, the 8q24 region has recently been identified in a large-scale study across human cancers as the most frequently amplified region (14%; Beroukhim et al., [@B9]). Detailed studies of individual cancer type studies have also revealed extensive evidence of gene amplification involving the chr.8q24 region, often with reference to increased *MYC* copy number and/or increased MYC expression. Although most reports focus primarily on *MYC* as the target of these amplification events, more detailed analyses with additional probes often finds adjacent regions of 8q24 within these amplicons. *MYC* amplification, for example, is considered to be a prognostic marker of early stage lung adenocarcinoma (ADC) as *MYC* amplification correlates with poor prognosis (Iwakawa et al., [@B42]). Specifically five sub-regions of amplification were defined in the chr.8q24 region including a *MYC* containing sub-region three in 10.8% of primary lung ADCs (*n* = 65) and 25% of lung ADC cell lines (*n* = 40). While *PVT1* and *miR-1208* mapped to what the authors refer to as amplification sub-region four, no other sub-regions (1, 2, or 5) corresponded to any candidate transcripts. In a sequencing study of the lung ADC cell line, NCI-H2171, a fusion gene comprised of *CHD7* and *PVT1* was identified (Campbell et al., [@B15]). Subsequent fusions between *CHD7* and exon 1 of *PVT1* were also identified in LU-135 (Pleasance et al., [@B62]). In another large study of lung ADC (*n* = 371), amplification identified by "Genomic Identification of Significant Targets in Cancer" (GISTIC) analysis focused on the region between 129.18 and 129.34 Mb (*q* = 9.06 × 10^−13^) that refers to *MYC* as the affected proto-oncogene (Weir et al., [@B82]). The more precise localization of this amplification is actually the region of distal *PVT1* and *miR-1208* (Figure [1](#F1){ref-type="fig"} -- Amplification-2).

Genomic Identification of Significant Targets in Cancer analysis in a study of 52 ovarian tumors found 59% with a gain of *MYC* and *PVT1* but only significant over-expression of *PVT1* relative to normal samples (Haverty et al., [@B37]). Consistent with these results are the combined studies of ovarian and breast cancer by Gray and colleagues that show *PVT1* and *MYC* contribute independently to pathogenesis with a strong correlation to overall chr.8q24 amplification (Guan et al., [@B32]). RNAi-mediated silencing in ovarian and breast cell lines showed reduced proliferation in 8q24 amplified cell lines for either *MYC* or *PVT1*, whereas silencing of just *PVT1* increased apoptosis and only in cell lines with amplification of 8q24. However, as mentioned above, no mechanistic explanation for the specificity of this observation in cell lines with amplified 8q24 has emerged as yet. High-resolution comparative genomic arrays of chromosome 8q have also been utilized in a study of gastroesophageal junction ADCs that include esophagus and cardia cancers (van Duin et al., [@B79]). Three commonly overexpressed regions of genomic gain were identified on chr.8q24 with the most distinctive encompassing *MYC* at 128--132 Mb. The other regions that were identified are between 124 and 127 Mb (referred to as Region 1) that included FAM84B and a region far downstream between 142 and 146 Mb (referred to as Region 4). In studies of expression of gastric esophageal junction tumors versus normal adjacent tissue, van Duin et al. ([@B79]) saw a significant increase in expression of MYC, but not FAM84B. Many examples of amplified chr.8q24, particularly those from older studies have exclusively compared expression of *MYC* without the benefit of knowing additional transcripts may exist. In this case, a large bulk of the literature contains evidence of chr.8q24 amplification in combination with *MYC* over-expression (Borg et al., [@B10]; Mangano et al., [@B53]; Kim et al., [@B46]). One of the first studies of *PVT1* transcription by Shtivelman and Bishop ([@B68]), intuitively suggested that *PVT1* or at least the first exon of *PVT1* may co-amplify with *MYC* and the expression of both *MYC* and *PVT*1 transcripts may be coordinately up-regulated. These findings arose from studies of amplified chr.8q24 in colon, SCLC, and neuroepithelioma cell lines. Additional studies also found co-amplification of the first exon of PVT1 and MYC in 2/26 cases of multiple myeloma (Bakkus et al., [@B6]). With the high frequency of co-amplification that seems to be focused on the immediate region surrounding *MYC*, *PVT1*, exons 1a and 1b, and *miR-1204* in many different tumors, we have designated this region 1 of amplification in 8q24 (Figure [1](#F1){ref-type="fig"} -- Amplification-1).

Chromosomal Translocation
=========================

The 8q region is among the earliest cytogenetic examples of a human chromosomal translocation (Zech et al., [@B88]). The T(8:14) translocation and subsequent variant translocations of T(8:22) and T(2:8) became the hallmark lesion in BL, a form of non-Hodgkin's lymphoma prevalent in sub-Saharan regions of Africa. Interestingly, it was the similar mouse B-cell disease, the plasmacytoma that suggested the first molecular recognition of *MYC* as the targeted fusion gene in the chr.8q24 region (Shen-Ong et al., [@B67]). Although other forms of non-Hodgkin's lymphoma such as a subset of diffuse large B-cell lymphoma, follicular lymphoma, or mantle cell lymphoma may also present with *MYC* translocations, the predominance of the chr.8q24-based translocation in BL has become the hallmark lesion for WHO designation as BL. While the fusion in most (frequency of 80%) of these diseases is between the immunoglobulin (Ig) heavy chain and *MYC*, variant translocations (at a frequency of 20%) also implicating the chr.8q24 region but with a different fusion partner (Ig light chain genes) are also recognizable BL specific lesions. The target of essentially all variant translocations to the Ig light chain genes is *PVT1*. Some T cell leukemias also carry T(8;14) translocations but the fusion partner is one of the TCR loci (*TCR alpha* or *delta* juxtaposed to either *MYC* or *PVT1*. In a very interesting study describing the cytogenetic events associated with a rare disease of hematodermic neoplasm, the authors have identified a series of changes including deletion of the region 3′ of *PVT1* (Jardin et al., [@B43]). What they report is an arrest of plasmacytoid dendritic cells at the G1/S transition possibly connected to the loss of several miRNAs (*miR-1206*, *miR-1207*, and *miR-1208*) from the Chr.8q24 cluster (Jardin et al., [@B43]).

Viral Integration
=================

Infection with human papilloma virus (HPV) is believed to be important in the pathogenesis of anogenital carcinomas and other epithelial carcinomas (zur Hausen, [@B89]). It is also believed the HPV will persist in an epifocal state in early dysplasia with the presence of E6 and E7 proteins capable of interfering with cellular control mechanisms. Eventual integration of HPV into the genome is found in advanced and high risk carcinomas that might suggest the additional recruitment of cellular oncogenes in the transformation process. However, the essential randomness of HPV integration throughout the entire genome makes the argument of a specific target tenuous at best. The most common site of HPV integration in genital neoplasia (10.7% or 26/243) is the Chr.8q24 region with two sub-clusters of integration sites around 500 and 60 kb upstream of MYC (Durst et al., [@B20]; Popescu et al., [@B65]; Peter et al., [@B61]). Originally, it was thought that only HPV18 integrated into the 8q24 locus (Ferber et al., [@B26]), but more recent studies have documented HPV16 and HPV45 to be integrated into the 8q24 region as well (Peter et al., [@B61]; Kraus et al., [@B49]). In one of the most often-characterized cervical cancer cell lines, HeLa, integration of HPV18 into the 8q24 locus was identified with accompanying increased MYC expression. It now appears that the basis for the over-expression of MYC in HeLa and other ADCs with 8q24 integrated HPV sequences is co-amplification of *MYC* and adjacent sequences including *PVT1a*, *miR-1204* with the integrated viral sequences of HPV (Herrick et al., [@B38]; Peter et al., [@B61]). An important histological distinction has been noted in that ADCs frequently exhibit an 8q24 HPV integration whereas squamous cell carcinomas contain other random chromosomal integration events (Lombard et al., [@B52]; Peter et al., [@B61]). Thus, it may not be the type of HPV found integrated at 8q24 that is so important in the development of cervical CA, but the location and the accompanying amplification events.

Summary
=======

It is well known that the oasis is a small but significant component of the desert ecosystem. By analogy, it may be that the presence of not just the *MYC* oncogene, but also the adjacent loci of *PVT1*, *PRNCR1*, the miRNA cluster of *miR-1204* ∼ *1208* or *POU5F1P1* represent a more comprehensive transcriptional oasis in the 8q24 gene desert. In most studies involving the 8q24 locus, the *MYC* proto-oncogene is the focus of attention as neighboring non-coding transcripts have struggled for the establishment of functionality. However, it is often but not always the case that increased *MYC* expression is accompanied by increased expression of the neighboring transcripts, principally *PVT1*. The reason for this could be epigenetic (chromatin accessibility) or the suggestion that at least in one case, *MYC* binds to the promoter of *PVT1*, thereby activating *PVT1* and *miR-1204* transcription (Carramusa et al., [@B16]). Another means of co-activating *MYC*, *PVT1*, and *miR-1204* derives from the observed enhancer binding activity of the rs3983267 risk region to the promoters of *PVT1*, *MYC*, and *miR-1204* (Wright et al., [@B84]). In at least one study of the pathophysiology of ovarian and breast cancer, it has been shown that *MYC* and *PVT1* act independently and at least for *PVT1*, this action is mediated through apoptosis (Guan et al., [@B32]). Furthermore, this action may be associated specifically with amplification of the 8q24 region. Induction of apoptosis by over-expression of *miR-1204* and perhaps the other miRNAs in the *miR-1204* ∼ *1208* cluster as well suggests an anti-proliferative role for the miRNAs independent of *MYC* (Barsotti et al., [@B7]). Obviously, it will also be important to elucidate the specific nature of interactions between the *miR-1204* ∼ *1208* cluster and the non-coding *PVT1* host transcript as well. An interesting genetic analog to the *PVT1* region is human chromosome 13q14 that contains two miRNAs, *miR15a*, *miR-16-1*, within the intron 4 of the host non-coding transcript *DLEU2* (Migliazza et al., [@B57]). Although the specific role for *DLEU2* is not understood, it appears that deletion of the entire region is required in the development of an aggressive phenotype of chronic lymphocytic leukemia suggesting a combined role for miRNAs and a non-coding transcript (Klein et al., [@B47]). In this paper, we have attempted to raise the awareness of other transcripts besides *MYC* in the 8q24 region to emphasize possible roles they may play as well in what appears to one of the most cited regions (8q24) in the human genome.
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